Jay Bhattacharya and Matthew Memoli aren't bringing "gold standard science" to the #NIH, they are gutting research slowly but surely. When this time is over, they should be hauled before Congress, and shunned for the rest of their lives. www.nytimes.com/interactive/...

New publication by my PhD student on the scheduling & monitoring of gabapentin medications. “A comprehensive analysis of jurisdiction-specific laws related to scheduling or required prescription drug monitoring of #gabapentin in the United States, 2016–2024” www.sciencedirect.com/science/arti...

AMERSA invites proposals for podcast episodes, workshops, and toolkits addressing substance use care during pregnancy and parenting for the upcoming series, Substance Use Across the Lifespan. 🔗 Submit by 𝗗𝗲𝗰 𝟳, 𝟮𝟬𝟮𝟱 → amersa.org/2026-amersa-...

Proud of Brooke & our small but mighty team of drug checkers at SLO Bangers, presenting @amersa.org So great to hang w my social science collab “phone an anthropologist“ BFF sister @drteresa-winst.bsky.social (presented w her student on polydrug use) & w our LA DC fam @caitlinmolina.medsky.social

Thank you for being part of AMERSA 2025! We’re grateful for the learning, connection, and collaboration this week. Safe travels to all heading home—we look forward to continuing this work together and seeing you in Washington, DC in 2026!

“Best conference I’ve ever been to!” — Aleka Heinrici, family physician & addiction specialist at #AMERSA2025. Referred by a colleague, she came to the conference & paid it forward by inviting a Portland-based clinician. The conversations & energy here fuel better care & outcomes for people w/SUD.

Today’s Rich Saitz plenary brought powerful insights into the current evidence for psychedelics in addiction recovery from Adie Rae Wilson-Poe, PhD, Kevin Franciotti, and moderator Chris Stauffer, MD. Thank you to our speakers for a great discussion.

Our Special Interest Groups started the day with insightful dialogue. Learn more about AMERSA SIGs here: amersa.org/special-inte... #AMERSA2025

A full and inspiring first day at #AMERSA2025. Thought-provoking plenaries, outstanding oral abstracts, recognition of exceptional contributors, and a dynamic poster session brought our community together in meaningful ways.

Prescription Drug Monitoring Programs: Helpful or Harmful? Today's AMERSA Discourse session was a great exchange of perspectives - energizing, respectful, and especially fun. #AMERSA2025

“Visibility is vulnerability. You should not be helping to build tools that can be used against you.” Insight from @lizchiarello.bsky.social during today’s #AMERSA2025 discourse on PMPs. She explores the impact of this “Trojan horse technology” in her 2024 book, which I highly recommend!

What a start! Today’s Opening Plenary energized the room and launched #AMERSA2025 with purpose.

Nice to see this @jamanetworkopen.com paper first authored by Sophia Huebler, a PhD student (!) @utah.edu released today. #buprenorphine rx for #OUD has dramatically shifted to non-addiction specialty care settings in @deptvetaffairs.bsky.social @parcka.bsky.social jamanetwork.com/journals/jam...

Collaboration, conversation, and community — exactly what makes #AMERSA2025 so special.

It's finally here! #AMERSA2025 kicks off today with the annual board retreat and pre-conference workshops. I'm excited to (re)connect with the most innovative, compassionate, and community-engaged folks in substance use and addiction!

During his campaign, Trump (& RFK) promised to rein in the use of dangerous pesticides, but the EPA has loosened oversight and is accelerating pesticide approvals. Notably, the top 4 positions in the new Trump EPA’s chemical safety office are held by former pesticide and chemical industry lobbyists

The AMERSA team is hard at work preparing for an inspiring week of connection, learning, and community at #AMERSA2025. Check in early today from 12-6pm or tomorrow from 7am-7pm to be entered into a drawing to win complimentary 2026 registration in Washington, DC!

🆕editorial co-authored by CP3’s Dr. Julie Donohue argues that as health policy enters a turbulent era, research must focus not only on access, cost, & quality, but also on system innovations, SDoH, & emerging tools like AI. @jamahealthforum.com: jamanetwork.com/journals/jam...

New study from CP3 finds buprenorphine initiation in older adults rose in 2018–19 but plateaued thru 2021 despite access efforts—showing need for targeted implementation & clinician education to boost MOUD use. @agsjournal.bsky.social agsjournals.onlinelibrary.wiley.com/doi/full/10....

1/🔊 Our latest podcast focuses on the hollowed-out state of pain care in America. It asks "Why are we addicted to talking about opioids rather than helping people with chronic pain?" "On Becoming a Healer" is on Apple: podcasts.apple.com/us/podcast/o... Spotify: open.spotify.com/episode/2mU6...

Get support for opioid use disorder (OUD) without leaving home. Residents of Allegheny County, PA, can access same-day telemedicine evaluations, referrals to treatment, and more. Connect now: www.mattersnetwork.org/pa

I'm proud to serve on the board of this principled organization focused on substance use & addiction. We have fewer than 50 registration slots available for the next annual conference in November. Register now to learn from & connect with the brightest minds in the field! amersa.org/annual-confe...

Did you know that AMERSA provides $100,000 (over 1/10th of our budget!) in conference registration & travel support every year - without accepting any industry funding? Thank you to members, donors, and mission-aligned partners who support our efforts to include all voices at the table!

Methadone is one of the most studied, safest, & most effective medications for opioid use disorder (MOUD), cutting overdose risk by about half. But due to strict regulations, it’s only available through federally approved opioid treatment programs. Learn more at drugpolicy.org/resource/med...

[email protected] was diagnosed w/leukemia at 3 yrs old. He's now a pediatric resident & intends to become a pediatric oncologist. He just published his first op-ed describing the harm that removal of vaccine mandates will have on immunocompromised children. dcjournal.com/childhood-ca...

This proposed "compact" is an existential threat to academic integrity in the United States. If the targeted universities comply, direct federal interference in every aspect of university work will soon become the norm. www.nytimes.com/2025/10/02/o...

Here's the assignment folks. Write op-eds for your local papers and campus newspapers too. Just. Say. No. This is a classic authoritarian move and risks the future of higher education and science and innovation in the US. Speak out today. No time to lose. www.nytimes.com/2025/10/02/o...

New episode coming this Thursday! Episode 6 of AMERSA’s Stigma & Substance Use podcast spotlights innovators working to expand access to lifesaving methadone in hospitals and withdrawal management settings. Subscribe to new episode alerts: amersa.org/amersa-podcast/

The Vaccine Adverse Event Reporting System is getting attention bc RFK Jr. & his antivaxx goons plan to use VAERS to claim COVID vaccines killed children. This is an actual VAERS report for a reported death after COVID vaccine. This is what these people count as data showing “death after vaccine:”

House Republicans add to support for maintaining NIH budget in 2026 Both chambers of Congress have now rejected Trump’s proposed 40% cut www.science.org/content/arti...

Enough is enough. The health of the country is in danger. Read our resignation letters: insidemedicine.substack.com/p/breaking-n...

Demetre Daskalakis' resignation letter. One for the history books. www.hopiumchronicles.com/p/the-resign...

The MATTERS referral network has expanded into Allegheny County, Pennsylvania! Our new referral platform makes it simple for partners to connect people to treatment for substance use disorder in as little as 3 minutes. Learn more: mattersnetwork.org/referral-platform

Final Call! 🚨 Today is the last day to submit your nomination for AMERSA’s Nov 2025–Oct 2028 Board of Directors. Don’t miss your chance to help shape AMERSA’s future and make an impact in our community. Submit your self-nomination TODAY: amersa.org/amersa-board...

This week, my family had the privilege of participating in the AAC Institute's 2025 ICAN Talk Summer Camp! Silas is seven years old, autistic, and non-speaking. High-tech AAC devices can help him reach his full potential and maximize independence. www.linkedin.com/feed/update/...

It's not too late to register for the AMERSA 2025 Pre-Conference on Wednesday, November 12. Join us for one of three local site visits, an advocacy workshop, and a short film screening followed by a panel discussion! Register Now: tinyurl.com/RegisterAMER...

Register now for the best conference on substance use and addiction! @amersa.org ALWAYS fills up early. Researchers, educators, clinicians, harm reductionists, and all others addressing substance use challenges are welcome! #AMERSA2025 amersa.org/annual-confe...

Already registered for AMERSA 2025? Share this graphic and let others know you’ll be there! Let’s build excitement as we get ready to learn from and support one another this fall. We can’t wait to see you in Portland! Encourage your friends and colleagues to register: tinyurl.com/RegisterAMER...

The latest publication from the PhARM-OUD project – led by Tyler Varisco at the PhARM Program with funding from FORE – describes challenges and opportunities for improving buprenorphine access in pharmacies with a focus on wholesale distributors. doi.org/10.1016/j.da...

Congratulations to Dr. Pooja Lagisetty, the 2025 Best Research Abstract Award winner! We look forward to hearing Dr. Lagisetty present her work in November at the AMERSA Conference in Portland.

Appreciate this NYT coverage about Contingency Management, one of the most studied approaches to treating addiction- and one of our strongest tools to help people with stimulant use disorders. Rewards, not punishment! www.nytimes.com/2025/07/16/h...

It's time to cycle in new members for the @amersa.org Board of Directors! Researchers, educators, clinicians, paraprofessionals, & others engaged in addressing substance use challenges are welcome to self-nominate. Learn more about the BoD & apply now! amersa.org/amersa-board...

Last week, Pitt Pharmacy PERU staff came together for our first annual retreat. We closed with an outstanding seminar by Tyler Varisco from the UT Austin PhARM Program focused on pharmacy-level barriers to buprenorphine access! #PhARMOUD #FORE #NABP #NCPA youtu.be/FcTt9eYpJls

Congratulations to the 2025 Workforce Development Award Winners: Vanessa Mareno, DDS, MPH; Kaitlyn Small, BA, CARC; Kimber King; Axl Kaminski, JD, MA; Shane Stone, MD; and Jessica Machado, RN, BScN, MSN. We look forward to welcoming you at #AMERSA2025!

How can we make sense of current trends in the illicit drug supply and evaluate potential contributors to the recent decline in overdose deaths? Join us next week for Addiction Medicine Grand Rounds with Dr. Nabarun Dasgupta - in person and online! 🔗 medicine.yale.edu/internal-med...

The PhARM Program interviewed SSP participants in ATX to explore wound care knowledge & practices. Avoidance of conventional healthcare settings was common, & some practices were potentially harmful. Triage training for SSP staff is a promising solution. journals.sagepub.com/doi/10.1177/...

Congratulations to the AMERSA 2024 Best Workshop Award winner! This award, based on participant reviews, is presented each year to an outstanding workshop delivered at the annual conference. @ayeshaappamd.bsky.social @kinnathakarar.bsky.social @madelinemc5.bsky.social @katelcsw.bsky.social

One of the reasons our family relocated to Pittsburgh was to access services at the ICAN Talk Clinic for our nonspeaking autistic son. Please consider donating to support their summer camp so more kids like Silas can attend regardless of ability to pay! secure2.convio.net/hcf/site/TR;...

Trying to help identify a clinical pharmacist with experience in pediatric substance use disorder treatment for a presentation opportunity with a national pharmacy organization. Any recommendations?